Market Review on Acute Myelocytic LeukemiaAML, Acute Myeloblastic Leukemia-Pipeline Review, H1 2016

Acute Myelocytic LeukemiaAML, Acute Myeloblastic Leukemia-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects.

Complete report available @ Acute Myelocytic LeukemiaAML, Acute Myeloblastic Leukemia-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
- The report reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics and enlists all their major and minor projects
- The report reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

4SC AG AB Science SA AbbVie Inc. Acetylon Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. ADC Therapeutics Sarl Advenchen Laboratories, LLC Aeglea BioTherapeutics, Inc. Affichem SA Agios Pharmaceuticals, Inc. AIMM Therapeutics B.V. Akinion Pharmaceuticals AB Altor BioScience Corporation Amgen Inc. Antigen Express, Inc. Antisense Therapeutics Limited APIM Therapeutics AS Aprea AB arGEN-X BV Ariad Pharmaceuticals, Inc. Arno Therapeutics, Inc. Arog Pharmaceuticals, Inc. Array BioPharma Inc. Astellas Pharma Inc. Asterias Biotherapeutics, Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc Atara Biotherapeutics, Inc. Athenex, Inc.etc,.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###